Specialty Pharmaceuticals Canada

A Bold New Allergan

Actavis Specialty Pharmaceuticals Co., is the Canadian subsidiary of Actavis plc (NYSE: ACT). We are engaged in the marketing, sale and distribution of branded pharmaceutical products within the Canadian market.

On March 17, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma.


News Archive


We are focused on delivering innovative products that address key therapeutic categories in Women's Health, Gastroenterology, and Urology.

Fibristal TM Actavis Canada

In Canada, Actavis specialty products include Fibristal™, Lolo™, Asacol 800®, and Tudorza™ Genuair™

More about Actavis products

Global R&D

Actavis has a growing Specialty Brands pipeline, driven by Women’s Health, Gastroenterology and Urology products.

Actavis continues to focus its business development efforts on finding new opportunities to invest in this business and to add additional products to the pipeline.

Our pipeline currently has a number of products in various stages of development in Women’s Health, Gastroenterology and Urology.

Learn about R&D at Actavis